OncoMatch/Clinical Trials/NCT07302347
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Is NCT07302347 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Pembrolizumab for malignant neoplasm.
Treatment: Pembrolizumab — Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IIB, IIC, III, IV
Stage IIB, IIC, III or IV cutaneous melanoma; locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma; locally-advanced, or metastatic solid malignancy; metastatic MCC (Stage IV)
Prior therapy
Must have received: surgery — adjuvant
surgically completely resected ... melanoma
Must have received: locoregional therapy (surgery and/or radiation therapy) — locoregional
MCC that has recurred following standard locoregional therapy with surgery and/or radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify